Table 1 Five drugs against PD-1/PD-L1
Drug | Trademark | Owner | Drug target | Approval date |
|---|---|---|---|---|
Pembrolizumab | Keytruda | MSD | PD-1 | Sep 2014 |
Nivolumab | Opdivo | BMS | PD-1 | Dec 2014 |
Atezolizumab | Tecentriq | Roche | PD-L1 | May 2016 |
Avelumab | Bevancio | EMD and Pfizer | PD-L1 | Mar 2017 |
Durmalumab | Imfinzi | Astra Zeneca | PD-L1 | May 2017 |